Susquehanna International Group, LLP Ligand Pharmaceuticals Inc Transaction History

Susquehanna International Group, LLP

$688 Billion
Q2 2025

A detailed history of Susquehanna International Group, LLP transactions in Ligand Pharmaceuticals Inc stock. As of the latest transaction made, Susquehanna International Group, LLP holds 29,060 shares of LGND stock, worth $5.33 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

29,060

Previous 22,765 27.65%

Holding current value

$5.33 Million

Previous $2.39 Million 38.03%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$96.67 - $118.22 $608,537 - $744,194	6,295 Added 27.65%	29,060 $3.3 Million
Q1 2025 May 14, 2025	BUY	$105.14 - $122.23 $1.59 Million - $1.85 Million	15,151 Added 198.99%	22,765 $2.39 Million
Q4 2024 Feb 14, 2025	SELL	$99.95 - $129.9 $977,311 - $1.27 Million	-9,778 Reduced 56.22%	7,614 $815,000
Q3 2024 Nov 14, 2024	BUY	$82.7 - $110.11 $446,001 - $593,823	5,393 Added 44.95%	17,392 $1.74 Million
Q2 2024 Aug 15, 2024	SELL	$68.53 - $87.91 $206,617 - $265,048	-3,015 Reduced 20.08%	11,999 $1.01 Million
Q1 2024 May 07, 2024	SELL	$68.64 - $89.2 $17,983 - $23,370	-262 Reduced 1.72%	15,014 $1.1 Million
Q4 2023 Feb 14, 2024	BUY	$49.57 - $72.63 $199,866 - $292,844	4,032 Added 35.86%	15,276 $1.09 Million
Q3 2023 Nov 14, 2023	BUY	$58.86 - $72.67 $256,453 - $316,623	4,357 Added 63.26%	11,244 $673,000
Q2 2023 Aug 11, 2023	SELL	$69.53 - $79.33 $15,366 - $17,531	-221 Reduced 3.11%	6,887 $496,000
Q1 2023 May 16, 2023	SELL	$65.67 - $77.08 $375,041 - $440,203	-5,711 Reduced 44.55%	7,108 $522,000
Q4 2022 Feb 14, 2023	SELL	$61.72 - $96.74 $179,296 - $281,029	-2,905 Reduced 18.47%	12,819 $856,000
Q3 2022 Nov 14, 2022	BUY	$0.01 - $107.56 $157 - $1.69 Million	15,724 New	15,724 $1.35 Million
Q1 2022 May 16, 2022	SELL	$94.99 - $151.56 $136,690 - $218,094	-1,439 Reduced 10.34%	12,482 $1.4 Million
Q4 2021 Feb 14, 2022	BUY	$127.69 - $165.85 $257,550 - $334,519	2,017 Added 16.94%	13,921 $2.15 Million
Q3 2021 Nov 15, 2021	SELL	$102.33 - $144.73 $3.45 Million - $4.88 Million	-33,695 Reduced 73.89%	11,904 $1.66 Million
Q2 2021 Aug 11, 2021	BUY	$113.03 - $155.64 $4.92 Million - $6.77 Million	43,494 Added 2066.22%	45,599 $5.98 Million
Q1 2021 May 17, 2021	SELL	$99.52 - $215.83 $5.35 Million - $11.6 Million	-53,740 Reduced 96.23%	2,105 $321,000
Q4 2020 Feb 16, 2021	BUY	$80.55 - $106.05 $4.19 Million - $5.51 Million	51,978 Added 1344.14%	55,845 $5.55 Million
Q3 2020 Nov 16, 2020	SELL	$89.56 - $126.72 $44,690 - $63,233	-499 Reduced 11.43%	3,867 $369,000
Q2 2020 Aug 14, 2020	SELL	$68.28 - $123.65 $697,548 - $1.26 Million	-10,216 Reduced 70.06%	4,366 $489,000
Q1 2020 May 15, 2020	BUY	$63.37 - $107.88 $502,650 - $855,704	7,932 Added 119.28%	14,582 $1.06 Million
Q4 2019 Feb 14, 2020	SELL	$96.94 - $113.59 $1.43 Million - $1.68 Million	-14,765 Reduced 68.95%	6,650 $694,000
Q3 2019 Nov 14, 2019	SELL	$86.25 - $120.16 $7.17 Million - $9.99 Million	-83,145 Reduced 79.52%	21,415 $2.13 Million
Q2 2019 Aug 16, 2019	BUY	$107.38 - $129.34 $307,643 - $370,559	2,865 Added 2.82%	104,560 $11.9 Million
Q2 2019 Aug 14, 2019	BUY	$107.38 - $129.34 $10 Million - $12.1 Million	93,262 Added 1105.92%	101,695 $11.6 Million
Q1 2019 May 15, 2019	BUY	$105.93 - $142.47 $468,846 - $630,572	4,426 Added 110.46%	8,433 $1.06 Million
Q3 2018 Nov 14, 2018	SELL	$211.18 - $274.49 $12.9 Million - $16.7 Million	-60,961 Reduced 93.83%	4,007 $1.1 Million
Q2 2018 Aug 14, 2018	BUY	$150.77 - $207.98 $3.64 Million - $5.02 Million	24,126 Added 59.07%	64,968 $13.5 Million
Q1 2018 May 15, 2018	BUY	$138.63 - $182.62 $5.66 Million - $7.46 Million	40,842 New	40,842 $6.75 Million

Others Institutions Holding LGND

# of Institutions

291

Shares Held

19.5M

Call Options Held

Put Options Held

View Full List

About LIGAND PHARMACEUTICALS INC

Ticker LGND
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 16,882,800
Market Cap $3.09B
Description
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...

More about LGND

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account

Susquehanna International Group, LLP Ligand Pharmaceuticals Inc Transaction History